

ivosidenib (Tibsovo®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2664	as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who were previously treated by at least one prior line of systemic therapy.	Available in line with local or regional guidance	09/09/2024	15/11/2024
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8577/ivosidenib-tibsovo-final-august-2024-for-website.pdf				

dabrafenib (Finlee®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2667	in combination with trametinib (Spexotras®) for: <ul style="list-style-type: none"> the treatment of paediatric patients aged 1 year and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. the treatment of paediatric patients aged 1 year and older with high-grade glioma with a BRAF V600E mutation who have received at least one prior radiation and / or chemotherapy treatment. 	Not routinely available as the ADTC is waiting for further advice from local clinical experts	09/09/2024	15/11/2024
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8575/dabrafenib-finlee-final-august-2024-for-website.pdf				

teclistamab (Tecvayli)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2668	as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/09/2024	15/11/2024
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8572/teclistamab-tecvayli-final-august-2024-for-website.pdf				
elranatamab (Elrexfio®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2669	as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	09/09/2024	15/11/2024
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8576/elranatamab-elrexfio-final-august-2024-amended-20240902-for-website.pdf				

pegcetacoplan (Aspaveli®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2715	as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.	Not routinely available as not recommended for use in NHS Scotland	09/09/2024	21/08/2024
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/8571/pegcetacoplan-aspaveli-non-sub-final-august-2024-for-website.pdf				
volanesorsen (Waylivra®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2716	as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.	Not routinely available as not recommended for use in NHS Scotland	09/09/2024	21/08/2024
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/8573/volanosorsen-waylivra-non-sub-final-august-2024-for-website.pdf				

zilucoplan (Zilbrysq®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2717	as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.	Not routinely available as not recommended for use in NHS Scotland	09/09/2024	21/08/2024
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/8574/zilucoplan-zilbrysq-non-sub-final-august-2024-for-website.pdf				